Comparative Pharmacology
Head-to-head clinical analysis: DIAZEPAM versus DORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIAZEPAM versus DORAL.
DIAZEPAM vs DORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
Anxiety: 2-10 mg PO BID-QID; Sedation/Muscle spasm: 5-10 mg IV/IM q3-4h PRN; Status epilepticus: 0.15-0.2 mg/kg IV (max 10 mg) q10-15 min PRN.
15-30 mg orally at bedtime, maximum 60 mg/day.
None Documented
None Documented
Terminal half-life 30-56 hours (range 20-70 hours) in adults; prolonged in elderly (up to 100 hours), neonates (up to 100 hours), and cirrhosis (up to 100+ hours).
Clinical Note
moderateDiazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Diazepam is combined with Fluticasone propionate."
Clinical Note
moderateFludiazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluticasone propionate."
Clinical Note
moderateDiazepam + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Diazepam."
Clinical Note
moderateTerminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Renal (70-80% as metabolites, primarily glucuronide conjugates; <5% unchanged), fecal (10-20% as metabolites), biliary (minor).
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
Diazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Diazepam."